AIOM 2021 - XXIII National Congress of Italian Association of Medical Oncology
Oct 22 - Oct 24, 2021 | RomeItaly
LARVOL is not affiliated with XXIII National Congress of Italian Association of Medical Oncology and all trademarks, logos, and brand names are property of their respective owners
Showing 33 abstracts linked to Trials
PATIENTS’ QUALITY OF LIFE AND SIDE EFFECT PERCEPTIONS IN MONARCHE, A STUDY OF ABEMACICLIB PLUS ENDOCRINE THERAPY IN ADJUVANT TREATMENT OF HR+, HER2-, NODE-POSITIVE, HIGH-RISK, EARLY BREAST CANCER
THE PROGNOSTIC PERFORMANCE OF PREDICT+ IN PATIENTS (PTS) WITH HER2-POSITIVE (HER2+) EARLY-STAGE BREAST CANCER (EBC)
SURVIVAL OUTCOMES OF TRIPLE NEGATIVE BREAST CANCER (TNBC) PATIENTS IN THE PRE-IMMUNOTHERAPY AGE. AN ANALYSIS OF GRUPPO ITALIANO MAMMELLA (GIM) 14 BIOMETA STUDY WITH A FOCUS ON BIOLOGICAL SUBTYPES
EFFICACY OF NIRAPARIB BY TIMING OF SURGERY AND RESIDUAL DISEASE: A POST HOC ANALYSIS OF PATIENTS IN THE PRIMA/ENGOT-OV26/GOG-3012 STUDY
NIVOLUMAB PLUS CABOZANTINIB (N+C) VS SUNITINIB (S) FOR ADVANCED RENAL CELL CARCINOMA (ARCC): OUTCOMES BY BASELINE DISEASE CHARACTERISTICS IN THE PHASE 3 CHECKMATE 9ER TRIAL
REAL-WORLD STUDY OF CABOZANTINIB IN PTS WITH ADVANCED RENAL CELL CARCINOMA (ARCC) AFTER VEGF-TARGETED THERAPY (CASSIOPE): INTERIM DATA FOR PATIENTS WHO HAD RECEIVED PRIOR NIVOLUMAB
CEMIPLIMAB MONOTHERAPY AS FIRST-LINE (1L) TREATMENT OF PATIENTS (PTS) WITH BRAIN METASTASES (METS) FROM ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) WITH PROGRAMMED CELL DEATH-LIGAND 1 (PD-L1) >=50%; EMPOWER-LUNG 1 SUBGROUP ANALYSIS
5-YEAR OVERALL SURVIVAL (OS) IN COLUMBUS: A RANDOMIZED PHASE 3 TRIAL OF ENCORAFENIB PLUS BINIMETINIB VERSUS VEMURAFENIB OR ENCORAFENIB IN PATIENTS (PTS) WITH BRAF V600-MUTANT MELANOMA
OSTENONECROSIS OF THE JAW (ONJ) AFTER DENOSUMAB IN GIANT CELL TUMOR OF BONE (GCTB): A SINGLE INSTITUTION ANALYSIS OF PATIENTS WITH RESECTABLE AND UNRESECTABLE TUMORS ENROLLED IN A PROSPECTIVE, INTERNATIONAL STUDY 20062004
CLINICAL AND HISTOLOGICAL PROGNOSTIC FACTORS OF MALIGNANT TRANSFORMATION IN A LARGE SERIES OF ORAL POTENTIALLY MALIGNANT DISORDERS (OPMDS)
EXTENDED THERAPY WITH LETROZOLE AS ADJUVANT TREATMENT OF POSTMENOPAUSAL PATIENTS WITH EARLY-STAGE BREAST CANCER: A RANDOMISED, PHASE 3 TRIAL OF THE GRUPPO ITALIANO MAMMELLA
PHASE II STUDY OF PREOPERATIVE (PREOP) CHEMORADIOTHERAPY (CTRT) PLUS AVELUMAB (AVE) IN PATIENTS (PTS) WITH LOCALLY ADVANCED RECTAL CANCER (LARC): THE AVANA STUDY
MAYA TRIAL: TEMOZOLOMIDE (TMZ) PRIMING FOLLOWED BY COMBINATION WITH LOW-DOSE IPILIMUMAB AND NIVOLUMAB IN PATIENTS WITH MICROSATELLITE STABLE (MSS), MGMT SILENCED METASTATIC COLORECTAL CANCER (MCRC)
BEVERLY: A MULTICENTER, RANDOMIZED, PHASE III TRIAL OF BEVACIZUMAB + ERLOTINIB VS ERLOTINIB ALONE AS FIRST-LINE TREATMENT OF PTS WITH EGFR-MUTATED, NON-SQUAMOUS, ADVANCED NSCLC
OVERALL SURVIVAL IN METASTATIC BREAST CANCER PATIENTS ACCORDING TO DIFFERENT FOLLOW UP STRATEGIES FOR EARLY BREAST CANCER